mytatrienediol mytatrienediol mytatrienediol (developmental code name sc-6924; former tentative brand names manvene, anvene), also known as 16α-methyl-16β-epiestriol 3-methyl ether or 16β-hydroxy-16α-methylestradiol 3-methyl ether, is a synthetic steroidal estrogen medication and an estrogen ether which was derived from estriol and was developed for clinical use in the late 1950s but was never marketed. it was investigated as a weak and mildly estrogenic medication for men to treat atherosclerosis, improve serum lipid profiles, and reduce the risk of myocardial infarction. however, while preclinical research supported the profile of mytatriendiol as a weak estrogen, the medication was found in clinical trials to produce estrogenic side effects including feminization, breast pain, and gynecomastia in men similarly and comparably to other estrogens such as ethinylestradiol and conjugated estrogens, and its side effects ultimately precluded its use. the medication was also studied to treat bone pain in patients with multiple myeloma, metastatic bone disease, and osteoporosis, with effectiveness seen. mytatrienediolclinical dataother namessc-6924; manvene; anvene; 3-methoxy-16α-methylestra-1,3,5(10)-triene-16β,17β-diol; 16α-methylestriol 3-methyl ether; 16β-hydroxy-16α-methylestradiol 3-methyl etherroutes ofadministrationby mouthdrug classestrogen; estrogen etheridentifiers iupac name (8r,9s,13s,14s,16s,17r)-3-methoxy-13,16-dimethyl-7,8,9,11,12,14,15,17-octahydro-6h-cyclopentaphenanthrene-16,17-diol cas number5108-94-1pubchem cid5282364chemspider4445527unii1g3tkh1o14keggc14242chebichebi:34859comptox dashboard (epa)dtxsid1022500 chemical and physical dataformulac20h28o3molar mass316.441 g·mol−13d model (jsmol)interactive image smiles cc12ccc3c(c1cc(c2o)(c)o)ccc4=c3c=cc(=c4)oc inchi inchi=1s/c20h28o3/c1-19-9-8-15-14-7-5-13(23-3)10-12(14)4-6-16(15)17(19)11-20(2,22)18(19)21/h5,7,10,15-18,21-22h,4,6,8-9,11h2,1-3h3/t15-,16-,17+,18-,19+,20+/m1/s1key:oovxzfcpcsvsem-nadogsgzsa-n